INS and metabolic dysfunction-associated steatohepatitis: In line with the observations made in the above mice model with NASH, 2‐BP treatment did not alter rabbits body weight, but as expected from dose‐dependent 2‐BP‐treated mice, it far lowered serum free fatty acid (FFA) levels (Figure S17h, Supporting Information), abnormal serum lipid contents (i.e., TG, TC, LDLC, and HDLC) (Figure S17i, Supporting Information), dysregulated blood glucose and insulin levels (Figure S17j, Supporting Information).